GSK

14 proposals selected from 428 entries in 26 countries Project areas include HIV, cancer and neurodegeneration LONDON, 4-12-2014 — /EuropaWire/ — GSK has announced the winners of its second Discovery Fast Track Challenge – a programme designed to combine the … Read the full press release →

LONDON, 13-11-2014 — /EuropaWire/ — GSK today announced the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorisation for eltrombopag (Revolade™), seeking an additional indication for the treatment of adult patients with severe aplastic anaemia … Read the full press release →

Developers encouraged to request accelerated procedure for scientific advice LONDON, 30-10-2014 — /EuropaWire/ — The European Medicines Agency (EMA) has given scientific advice to GSK on its development plan for an Ebola vaccine. This is the first time in the … Read the full press release →

CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza segments of Novartis Vaccines to GlaxoSmithKline Basel, Switzerland, 28-10-2014 — /EuropaWire/ — Novartis today … Read the full press release →

LONDON, 9-10-2014 — /EuropaWire/ — Stiefel, a GSK company, today announced the start of a phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with pemphigus vulgaris, a rare autoimmune skin disorder. The global study … Read the full press release →

LONDON, 9-10-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015. On appointment, Mr Rohner will also become a member of GSK’s Remuneration … Read the full press release →

LONDON, 10-9-2014 — /EuropaWire/ — GSK today presented data at the European Respiratory Society (ERS) Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an … Read the full press release →

LONDON, 10-9-2014 — /EuropaWire/ — GSK today announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK’s Africa NCD Open Lab initiative. The … Read the full press release →

MANCHESTER, 7-8-2014 — /EuropaWire/ — The Co-operative Group (“The Co-operative”) today announces the sale of its Farms business to the Wellcome Trust* (“the Trust”). The sale reflects The Co-operative’s decision to focus on its core Retail and Consumer Services divisions, including Food, Funeralcare, General … Read the full press release →

London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine, an investigational medicine which is being developed for the treatment and … Read the full press release →

London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Now licensed across … Read the full press release →

Marks GSK’s fourth Breakthrough Therapy designation London, UK, 17-1-2014 — /EuropaWire/ —  GlaxoSmithKline plc (LSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar®(dabrafenib) for treatment of patients with metastatic BRAF V600E … Read the full press release →